GHRP-6 Οξικός (Examorelin)

📦 Κάθε παραγγελία καλύπτεται από την Πολιτική Εγγύησης Επαναποστολής — εάν το δέμα σας δεν φτάσει εντός 20 εργάσιμων ημερών, το επαναποστέλλουμε.

What Is GHRP-6 Acetate?

GHRP-6 (Growth Hormone Releasing Peptide 6) is a 6-amino-acid synthetic hexapeptide and one of the canonical members of the growth hormone secretagogue (GHS) peptide class. It was developed by Cyril Y. Bowers and colleagues at Tulane University as part of a structure-activity relationship programme designed to identify small peptides capable of stimulating pulsatile growth hormone release from the anterior pituitary — work that ultimately led to the discovery of the growth hormone secretagogue receptor and, indirectly, to the identification of endogenous ghrelin as its natural ligand in 1999 by Kojima et al. (Nature). The acetate counterion is used in research-grade lyophilization because it improves long-term peptide stability and aqueous solubility without altering pharmacology.

The well-characterised sequence is HwAWfK-NH₂ (where lowercase letters denote D-amino acid residues), molecular weight 873.02 Da, empirical formula C₄₆H₅₆N₁₂O₆. The two D-amino-acid substitutions (D-Trp at position 2 and D-Phe at position 5) confer resistance to endogenous proteases and extend the in-vivo half-life relative to all-L analogs. The C-terminus is amidated, which is essential for receptor activity. GHRP-6 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. The research-grade GHRP-6 acetate sold here is supplied for laboratory research use only and is not intended for human or veterinary administration. For the newer-generation receptor-selective analog without cortisol/prolactin signalling, see our Ιπαμορελίνη product page.

Mechanism of Action — GHS-R1a Receptor Agonism and the GH Pulse

What makes GHRP-6 mechanistically distinctive among growth-axis research peptides is its selective action on the growth hormone secretagogue receptor — the same receptor activated by endogenous ghrelin — rather than the GHRH receptor used by sermorelin and CJC-1295. The downstream effect is a pulsatile rather than tonic pattern of GH release in published research:

• GHS-R1a receptor agonism on somatotrophs — GHRP-6 binds the growth hormone secretagogue receptor type 1a (GHS-R1a, also called ghrelin receptor) on anterior-pituitary somatotrophs. Receptor activation couples to Gα_q/11 and phospholipase C, raising intracellular calcium and triggering depolarisation-coupled exocytosis of GH-containing vesicles. The signal is amplified by suppression of somatostatin tone — GHRP-6 acts both at the somatotroph and at hypothalamic somatostatin neurons, producing a larger GH pulse than direct somatotroph stimulation alone would predict.
• Synergy with endogenous GHRH — The GHS-R and GHRH-R pathways converge intracellularly but use different second-messenger systems (PLC/IP₃/Ca²⁺ vs adenylyl cyclase/cAMP/PKA), so GHRP-6 and GHRH analogs produce additive or synergistic GH release when combined. This is the rationale for the canonical “GHRP + GHRH analog” research combinations: a GHS such as GHRP-6 paired with a GHRH analog such as Σερμορελίνη ή CJC-1295 with DAC. The combined stimulus produces GH pulses substantially larger than either compound alone.
• Off-target appetite stimulation and modest cortisol/prolactin signal — Because GHRP-6 acts on the ghrelin receptor, it inherits ghrelin’s appetite-stimulating effect — useful in cachexia research, but a confound in cleaner GH-axis pharmacology. GHRP-6 also produces a modest increase in cortisol and prolactin secretion. The newer-generation selective analog Ipamorelin was specifically designed to eliminate this cortisol/prolactin signal while preserving the GH effect — see the comparison section below.

GHRP-6 has a plasma half-life of approximately 30–60 minutes, considerably longer than native ghrelin (~10–30 minutes) due to the D-amino-acid substitutions that resist proteolytic cleavage. Subcutaneous administration is the most-cited research route in the published literature; intravenous and intranasal routes are also documented in mechanism-of-action studies.

Published Research Applications

GHRP-6 is used in laboratory research contexts that investigate:

• Growth hormone axis pharmacology — pulsatile GH dynamics, somatotroph responsiveness, comparative GH-secretagogue research; benchmark first-generation GHS in published GH-pulse architecture studies (Bowers et al., J Clin Endocrinol Metab; Smith et al., Science 1996)
• Appetite and feeding behaviour research — ghrelin-axis activation, food-intake assays in rodent models, cachexia models in tumour-bearing animals; canonical research tool for separating ghrelin-mediated orexigenic signalling from other appetite pathways
• Pituitary function research — GH reserve testing in preclinical models, somatotroph hypertrophy / hyperplasia, mechanism-of-action research for novel GH secretagogues
• Cachexia and wasting syndrome research — tumour-bearing rodent cachexia, COPD-associated wasting models, lean-mass / fat-mass preservation through combined GH-axis and appetite-axis activation
• Comparative GHS research — head-to-head benchmarking against newer analogs including Ιπαμορελίνη (receptor-selective without cortisol/prolactin), hexarelin (modified GHRP-6), GHRP-2 (alternative first-generation analog), and orally-active small-molecule GHS such as MK-677
• Cardiovascular research — GHS-R expression on cardiomyocytes; published research on cardiac ischaemia-reperfusion injury and cardiac function in GH-deficient models
• Combined GHRP + GHRH research — synergistic GH-release protocols pairing GHRP-6 with GHRH analogs such as Σερμορελίνη ή CJC-1295 with DAC for maximal pulsatile GH research stimulus.

For broader context on where GHRP-6 fits within the growth-axis peptide landscape, see Ιπαμορελίνη as the newer-generation receptor-selective analog, CJC-1295 with DAC for long-acting GHRH-axis research, and Σερμορελίνη for shorter-acting GHRH research. Browse the full research peptides catalog for related compounds.

Available Strengths and Concentrations

MedsBase stocks GHRP-6 Acetate in two lyophilized vial sizes calibrated to typical research protocol lengths. Each strength is available in 10-vial or 20-vial pack formats with full reconstitution guidance:

Both strengths are the same chemical form (lyophilized acetate-salt powder, 99%+ HPLC purity). Higher-mg vials require smaller reconstitution volumes per unit dose, which is useful when researchers want to minimise injection volume in rodent protocols. Because GHRP-6 dose ranges are in the 50–300 mcg per administration regime, a single 5 mg vial supports many weeks of research at typical doses.

How It Compares — GHRP-6 vs Ipamorelin

GHRP-6 and Ιπαμορελίνη are the canonical first- and third-generation members of the growth hormone secretagogue peptide class, respectively, and are the most-cited head-to-head comparison in published GHS research. They share the same receptor (GHS-R1a) and produce comparable GH pulses, but differ substantially in receptor selectivity and off-target signalling.

For research where the appetite-stimulation signal is a feature (cachexia models, food-intake studies), GHRP-6 is preferred because the orexigenic effect is part of the research target. For clean GH-axis pharmacology where cortisol and prolactin are confounding variables, Ipamorelin is preferred because the receptor-selectivity gains eliminate those off-target signals. Both are frequently paired with a GHRH analog (such as CJC-1295 with DAC) for the canonical synergistic GH-pulse research protocol.

Storage and Reconstitution

Before reconstitution: store lyophilized vials refrigerated at 2–8 °C in original packaging for short-term working stock. For unopened long-term storage, freeze at −20 °C. Lyophilized GHRP-6 acetate is stable under refrigeration for up to 24 months and at −20 °C for up to 36 months. Avoid freeze-thaw cycles on the lyophilized powder.

Reconstitution procedure: inject bacteriostatic water down the side wall of the peptide vial (not directly onto the lyophilized cake). For a 5 mg vial, 2.0 mL of bacteriostatic water yields a 2.5 mg/mL working concentration — 0.04 mL delivers a 100 mcg research dose; 0.1 mL delivers 250 mcg. Swirl gently — do δεν shake — and allow 2–5 minutes for full dissolution. A correctly reconstituted solution should be clear and colourless.

After reconstitution: store refrigerated at 2–8 °C and use within 30 days for optimal stability. Do not freeze the reconstituted solution — freeze-thaw cycles degrade peptide integrity. Discard any vial showing cloudiness, precipitate, or discolouration.

Συχνές Ερωτήσεις

What is GHRP-6 used for in research?

GHRP-6 is used in laboratory research investigating the growth hormone axis, pulsatile GH release dynamics, somatotroph responsiveness, ghrelin-axis pharmacology, appetite and feeding behaviour, cachexia and wasting syndromes, and combined GHRP + GHRH synergistic GH-release protocols. It is the canonical first-generation GHS research peptide and the structural template from which Ipamorelin and other later-generation analogs were derived. The research-grade GHRP-6 sold here is δεν FDA-approved and is supplied strictly for laboratory research use only.

How is GHRP-6 different from Ipamorelin?

Both act on the same receptor (GHS-R1a, the ghrelin receptor) and produce comparable pulsatile GH release, but they differ substantially in receptor selectivity and off-target signalling. GHRP-6 produces ghrelin-like appetite stimulation and modest increases in cortisol and prolactin. Ipamorelin was specifically designed to eliminate these off-target signals while preserving the GH effect — it produces minimal appetite signal and no measurable cortisol or prolactin increase in published research. For clean GH-axis pharmacology, Ipamorelin is preferred; for research involving appetite as a target, GHRP-6 remains useful.

What is the difference between GHRP-6 and GHRP-2?

Both are first-generation hexapeptide growth hormone secretagogues from the Bowers laboratory programme. GHRP-2 is somewhat more potent on a per-mg basis and produces slightly less appetite signal than GHRP-6, but the qualitative pharmacology is similar — both raise cortisol and prolactin modestly. GHRP-6 is the more extensively studied of the pair in published research and remains the canonical first-generation reference compound.

What is the typical GHRP-6 research dose?

Published preclinical protocols typically use 50–300 mcg per administration, given subcutaneously 1–3 times daily for 2–12 week research cycles. A 5 mg vial reconstituted with 2.0 mL bacteriostatic water yields 2.5 mg/mL — 0.04 mL equals 100 mcg, 0.1 mL equals 250 mcg.

Is GHRP-6 FDA approved?

No. GHRP-6 is not approved by the FDA, EMA, MHRA, or any other major regulator for human therapeutic use. All GHRP-6 sold by research-use-only suppliers is for laboratory investigation and should not be administered to humans.

How should GHRP-6 Acetate be stored?

Lyophilized vials: refrigerated at 2–8 °C for short-term working stock, or −20 °C for long-term storage of unopened vials. Reconstituted solution: refrigerated at 2–8 °C, use within 30 days. Do not freeze reconstituted solution — freeze-thaw cycles degrade the peptide. Protect from direct light at all times.

How do I reconstitute GHRP-6?

Follow the reconstitution procedure above. Add bacteriostatic water down the side wall of the vial (not onto the lyophilized cake), swirl gently, and allow 2–5 minutes for full dissolution. Do δεν shake the vial. A correctly reconstituted solution is clear and colourless. For a 5 mg vial + 2.0 mL diluent, the working concentration is 2.5 mg/mL.

What strengths does MedsBase stock?

MedsBase carries GHRP-6 Acetate in 5 mg and 10 mg lyophilized vials. Each strength is available in 10-vial or 20-vial pack sizes. All vials are supplied at 99%+ HPLC purity with a certificate of analysis available on request.

Why does GHRP-6 also stimulate appetite?

GHRP-6 binds the growth hormone secretagogue receptor (GHS-R1a) — the same receptor activated by endogenous ghrelin. Because ghrelin is the principal hunger hormone, any agonist of its receptor inherits some degree of orexigenic (appetite-stimulating) activity. For first-generation GHS such as GHRP-6 and GHRP-2, the appetite effect is substantial; for later-generation receptor-selective analogs such as Ipamorelin, the orexigenic signal was successfully attenuated through structural optimisation.

Can GHRP-6 be paired with a GHRH analog in research?

Yes — this is the canonical synergistic GH-pulse research protocol. GHRP-6 activates GHS-R1a (PLC/IP₃/Ca²⁺ signalling) while GHRH analogs such as Σερμορελίνη ή CJC-1295 with DAC activate GHRH-R (adenylyl cyclase/cAMP/PKA signalling). The two pathways converge on somatotrophs but use different second-messenger systems, producing additive or synergistic GH release when combined.

Does GHRP-6 cause side effects in research?

The principal on-target effects are GH release and appetite stimulation. Off-target findings include modest cortisol and prolactin increases (the principal research-relevant confound for GH-axis studies), transient flushing or local injection-site reactions, and (rarely) GHS-R-mediated effects on cardiac function at high doses. The cortisol/prolactin signal is the main reason newer-generation selective analogs such as Ipamorelin were developed.

What is the half-life of GHRP-6?

In preclinical research, GHRP-6 has a plasma half-life of approximately 30–60 minutes following subcutaneous administration. The extended half-life relative to endogenous ghrelin (~10–30 min) is due to the two D-amino-acid substitutions (D-Trp at position 2 and D-Phe at position 5) that resist proteolytic cleavage. The GH pulse outlasts plasma clearance because somatotroph desensitisation and receptor downregulation are slower processes.

How long does GHRP-6 take to show effects in preclinical research?

Acute GH pulses are detectable within 15–30 minutes of subcutaneous administration and peak within 60–90 minutes. Appetite-stimulation effects on food intake are measurable within hours of administration in rodent models. Downstream effects on IGF-1 production and tissue-level GH-axis signalling accumulate over 1–4 weeks of regular dosing.

Can I order GHRP-6 for international shipping?

Yes. MedsBase ships GHRP-6 worldwide from our dedicated peptide shipping network. Peptide-only orders qualify for our standalone peptide shipping service. All orders ship in temperature-controlled packaging with full tracking and are covered by our Πολιτική Εγγύησης Επαναποστολής.

Other Peptides for Growth-Axis, GH-Release, and Anabolic Research

• Ιπαμορελίνη — Third-generation selective GHS pentapeptide — clean GH pulse without cortisol/prolactin
• CJC-1295 with DAC — Long-acting GHRH analog — canonical GHRH-axis research compound
• Σερμορελίνη — Shorter-acting GHRH(1-29) analog — natural GH-pulse research
• IGF-1 LR3 — Long-arginine recombinant IGF-1 analog — downstream of GH/IGF axis
• Tesamorelin — GHRH analog — visceral adipose tissue research

Further Reading

Περισσότερες επιλογές σε Πεπτίδια

Ταξινομημένα σύμφωνα με τον όγκο παραγγελιών στο MedsBase — τι επιλέγουν άλλοι πελάτες σε αυτήν την κατηγορία.

BPC-157

US$115.00 – US$705.00Fascia di prezzo: da US$115.00 a US$705.00

Retatrutide

US$310.00 – US$6,515.00Fascia di prezzo: da US$310.00 a US$6,515.00

BAC Water (Bacteriostatic Water)

US$50.00 – US$150.00Fascia di prezzo: da US$50.00 a US$150.00

NAD⁺

US$210.00 – US$1,975.00Fascia di prezzo: da US$210.00 a US$1,975.00